BeiGene Ltd (BGNE)
190.92
-3.64
(-1.87%)
USD |
NASDAQ |
Nov 22, 10:06
BeiGene Shareholders Equity (Quarterly): 3.436B for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.436B |
| June 30, 2024 | 3.366B |
| March 31, 2024 | 3.360B |
| December 31, 2023 | 3.537B |
| September 30, 2023 | 3.763B |
| June 30, 2023 | 3.799B |
| March 31, 2023 | 4.157B |
| December 31, 2022 | 4.383B |
| September 30, 2022 | 4.655B |
| June 30, 2022 | 5.303B |
| March 31, 2022 | 5.886B |
| December 31, 2021 | 6.133B |
| September 30, 2021 | 3.357B |
| June 30, 2021 | 3.607B |
| March 31, 2021 | 4.004B |
| December 31, 2020 | 3.869B |
| September 30, 2020 | 4.287B |
| June 30, 2020 | 2.536B |
| March 31, 2020 | 2.812B |
| December 31, 2019 | 962.20M |
| Date | Value |
|---|---|
| September 30, 2019 | 1.278B |
| June 30, 2019 | 1.554B |
| March 31, 2019 | 1.609B |
| December 31, 2018 | 1.739B |
| September 30, 2018 | 1.970B |
| June 30, 2018 | 1.213B |
| March 31, 2018 | 1.344B |
| December 31, 2017 | 669.81M |
| September 30, 2017 | 750.14M |
| June 30, 2017 | 255.75M |
| March 31, 2017 | 308.42M |
| December 31, 2016 | 352.91M |
| September 30, 2016 | 187.83M |
| June 30, 2016 | 220.05M |
| March 31, 2016 | 243.10M |
| December 31, 2015 | 74.32M |
| September 30, 2015 | 100.08M |
| June 30, 2015 | 109.91M |
| December 31, 2014 | 25.77M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
962.20M
Minimum
Dec 2019
6.133B
Maximum
Dec 2021
3.861B
Average
3.781B
Median
Shareholders Equity (Quarterly) Benchmarks
| Theravance Biopharma Inc | 185.65M |
| Merck & Co Inc | 44.50B |
| Bristol-Myers Squibb Co | 17.14B |
| Zai Lab Ltd | 667.67M |
| Halozyme Therapeutics Inc | 452.70M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.831B |
| Total Liabilities (Quarterly) | 2.395B |
| Debt to Equity Ratio | 0.306 |
| Current Ratio | 1.931 |
| Net Debt Paydown Yield | -0.35% |